Status:
UNKNOWN
Combined Intravitreal Injection of Bevacizumab and Fasudil Versus Bevacizumab Alone for Macular Edema Secondary to Retinal Vein Occlusion in Previously Treated Patients
Lead Sponsor:
Shahid Beheshti University of Medical Sciences
Conditions:
Retinal Vein Occlusion
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
This study is aimed to compare the effect of combined intravitreal Bevacizumab and Fasudil injection with Bevacizumab only injection in patients with persistant macular edema secondary to ratinal vein...
Eligibility Criteria
Inclusion
- Branch retinal vein or central retinal vein occlusion Previous at least 3 intravitreal antiVEGF injection Macular edema in SD-OCT CMT = \>250 microns BCVA equal or lesd than 20/40
Exclusion
- Moderate or severe corneal opacity Significant cataract obscuring retinal exam or OCT Glaucoma History of vitreoretinal surgery Diabetic retinopathy Macular disease (AMD,ERM,VMT Kidney or Liver disease Uncontrolled or moderate or severe Anemia Uncontrolled hypertention
Key Trial Info
Start Date :
January 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2018
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT03391219
Start Date
January 1 2018
End Date
October 1 2018
Last Update
January 5 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ophthalmic Research Center
Tehran, Iran